Wednesday, December 22, 2010

Rivaroxaban

In the recent issue of NEJM results of two studies involving Rivaroxaban have been published. One was an open-label, randomized study that compared oral Rivaroxaban alone (15 mg twice daily for 3 weeks, followed by 20 mg once daily) with subcutaneous Enoxaparin followed by a vitamin K antagonist (either Warfarin or Acenocoumarol) for 3, 6, or 12 months in patients with acute, symptomatic DVT. 

 The second parallel study was a double blind, randomized, event-driven superiority study that compared rivaroxaban alone (20 mg once daily) with placebo for an additional 6 or 12 months in patients who had completed 6 to 12 months of treatment for venous thromboembolism.

The primary efficacy outcome for both studies was recurrent venous thromboembolism. The principal safety outcome was major bleeding or clinically relevant nonmajor bleeding in the initial-treatment study and major bleeding in the continued-treatment study.
The study of rivaroxaban for acute DVT included 3449 patients: 1731 given rivaroxaban and 1718 given enoxaparin plus a vitamin K antagonist. Rivaroxaban had noninferior efficacy with respect to the primary outcome (36 events [2.1%], vs. 51 events with enoxaparin–vitamin K antagonist [3.0%]; hazard ratio, 0.68; 95% confidence interval [CI], 0.44 to 1.04; P<0.001).
The principal safety outcome occurred in 8.1% of the patients in each group. In the continued-treatment study, which included 602 patients in the rivaroxaban group and 594 in the placebo group, rivaroxaban had superior efficacy (8 events [1.3%], vs. 42 with placebo [7.1%]; hazard ratio, 0.18; 95% CI, 0.09 to 0.39; P<0.001).
 Four patients in the rivaroxaban group had nonfatal major bleeding (0.7%), versus none in the placebo group (P=0.11).
The authors have concluded that Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation.
http://www.nejm.org/doi/full/10.1056/NEJMoa1007903

1 comment:

  1. I saw so many testimonies about Dr Itua a great HERBAL DOCTOR that can cure all kind of diseases and give you the rightful health to live a joyful life, i didn't believe it at first, but as the pain got worse and my life was at risk after visiting my therapist numeriuos times for combination of treatments. and no changes so i decided to take a try, I contacted him also and told him i want a cure for Vulvar cancer/ Testicular cancer and it was Stage IIIA, he gave me advice on what i must do and he delivered it to me in my state which i use according to his instruction, and today i must say I am so grateful to this man Dr Itua for curing me from Vulvar cancer/ Testicular cancer and for restoring me back to my normal health and a sound life,i am making this known to every one out there who have been living with cancers all his life or any sick person should not waist more time just contact him with his details below- WhatsApp- +2348149277967 Email drituaherbalcenter@gmail.com, believe me this man is a good man with Godly heart, this is the real secret we all have been searching for. Do not waste more time contact him today for you also to live a sound and happy life. he cure the following disease,thyroid Cancer,Uterine cancer,Fibroid,Angiopathy, Ataxia,Arthritis,Amyotrophic Lateral Scoliosis,Brain Tumor,Fibromyalgia, Fluoroquinolone Toxicity Bladder cancer,Brain cancer,Hiv,Herpes,Esophageal cancer,Gallbladder cancer,Gestational trophoblastic disease,Head and neck cancer,Hodgkin lymphoma
    Intestinal cancer,Kidney cancer,Hpv,Lung cancer,Melanoma,Mesothelioma,Multiple myeloma,Neuroendocrine tumors
    Non-Hodgkin lymphoma,Oral cancer,Ovarian cancer,Sinus cancer,Hepatitis A,B/C,Skin cancer,Soft tissue sarcoma,Stroke,Lupus,Spinal cancer,Stomach cancer,Vaginal cancer,Vulvar cancer,
    Testicular cancer,Tach Diseases,Pancreatic Cnacer,Leukemia,Liver cancer,Throat cancer,
    Syndrome Fibrodysplasia Ossificans ProgresSclerosis,Alzheimer's disease,Chronic Diarrhea,Copd,Parkinson,Als,Adrenocortical carcinoma  Infectious mononucleosis. 

    ReplyDelete